CN104491459A - Traditional Chinese medicine composition for treating tumors - Google Patents
Traditional Chinese medicine composition for treating tumors Download PDFInfo
- Publication number
- CN104491459A CN104491459A CN201510010589.8A CN201510010589A CN104491459A CN 104491459 A CN104491459 A CN 104491459A CN 201510010589 A CN201510010589 A CN 201510010589A CN 104491459 A CN104491459 A CN 104491459A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Abstract
The invention relates to a traditional Chinese medicine composition for treating tumors. The traditional Chinese medicine composition is prepared from the following raw materials drugs in parts by weight: 20-30 parts of solanum lyratum thumb, 5-15 parts of cordyceps sinensis, 10-15 parts of rhizoma paridis, 10-15 parts of air potatoes, 30-50 parts of astragalus, 2-3 parts of momordica cochinchinensis, 1-5 parts of scorpio, 12-18 parts of typhae pollen, 5-10 parts of white grubs, 20-50 parts of American ginseng, 20-50 parts of turtle shells, 20-50 parts of selfheal, 10-15 parts of edible tulip, 15-20 parts of fritillaria, 10-20 parts of pseudo-ginseng, 6-15 parts of ground beeltles, 20-30 parts of centipede, 30-50 parts of seaweeds and 10-15 parts of radix sophorae tonkinensis. The traditional Chinese medicine composition for treating tumors disclosed by the invention adopts natural drugs, has the effects of promoting blood circulation to remove blood stasis, activating meridians to stop pain, promoting the circulation of qi and breaking blood, removing qi stagnation and stopping bleeding, purging heat and dredging intestines, cooling blood, detoxifying, and the like, has the advantages of quick effect taking, good curative effect, no toxic or side effect and the like.
Description
Technical field
The present invention relates to field of medicaments, specifically, relate to a kind of Chinese medicine composition for the treatment of tumor.
Background technology
Hysteromyoma is one of modal tumor of pelvic cavity, and common method for the treatment of was based on hysterectomy in the past, but due to a variety of causes, many patients are difficult to accept.The main disease of uterus excision one of is planted.Research in recent years finds, uterus has endocrine function, can produce many active substances, participate in reproduction in body, physiology and pathological process, and hysterectomize before menopause, even if Ovary conservation, also often cause occurring ahead of time of climacteric syndrome, coronary heart disease and osteoporosis.Myomectomy patient, 50% can recur in a short time, so, Drug therapy hysteromyoma oneself more and more cause the attention of people.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition for the treatment of tumor.
In order to realize object of the present invention, the invention provides a kind of Chinese medicine composition for the treatment of tumor, it comprises the crude drug of following weight portion: Herba Solani Lyrati 20-30 part, Cordyceps 5-15 part, Rhizoma Paridis 10-15 part, Rhizoma Dioscoreae Bulbiferae 10-15 part, Radix Astragali 30-50 part, Semen Momordicae 2-3 part, Scorpio 1-5 part, Pollen Typhae 12-18 part, Holotrichia diomphalia Bates 5-10 part, Radix Panacis Quinquefolii 20-50 part, Carapax Trionycis 20-50 part, Spica Prunellae 20-50 part, Pseudobulbus Cremastrae Seu Pleiones 10-15 part, Bulbus Fritillariae Uninbracteatae 15-20 part, Radix Notoginseng 10-20 part, Eupolyphaga Seu Steleophaga 6-15 part, Scolopendra 20-30 part, Sargassum 30-50 part and Radix Sophorae Tonkinensis 10-15 part.
Preferably, the Chinese medicine composition for the treatment of tumor of the present invention comprises the crude drug of following weight portion: Herba Solani Lyrati 25 parts, Cordyceps 6 parts, Rhizoma Paridis 12 parts, Rhizoma Dioscoreae Bulbiferae 13 parts, the Radix Astragali 40 parts, Semen Momordicae 2.5 parts, Scorpio 2 parts, Pollen Typhae 15 parts, Holotrichia diomphalia Bates 8 parts, Radix Panacis Quinquefolii 30 parts, Carapax Trionycis 30 parts, Spica Prunellae 30 parts, Pseudobulbus Cremastrae Seu Pleiones 12 parts, Bulbus Fritillariae Uninbracteatae 18 parts, Radix Notoginseng 15 parts, Eupolyphaga Seu Steleophaga 10 parts, Scolopendra 25 parts, Sargassum 40 parts and Radix Sophorae Tonkinensis 12 parts.
More preferably, the Chinese medicine composition for the treatment of tumor of the present invention also comprises the crude drug of following weight portion: Radix Helicteris Isorae 10 parts, Pericarpium Citri Reticulatae 15 parts, Radix Ilicis Pernyi 20 parts, Radix Angelicae Sinensis 15 parts, Herba Blumeae Lacerae 12 parts, 20 parts, Flos Mume, Herba Limonii Gmelinii 20 parts, 15 parts, Radix Rubiae, Caulis Seu Folium Callicarpae Kwangtungensis 15 parts, Radix Bupleuri 10 parts, Herba Hedyotidis Chrysotrichae 20 parts, Caulis Bambusae In Taenia 10 parts and 12 parts, Radix Glycyrrhizae.
Most preferably, described Chinese medicine composition is tablet, dispersible tablet, rapidly dissolving tablet, powder, granule or decoction.
The present invention also provides the purposes of compositions in the Chinese medicine of preparation treatment tumor, and described compositions comprises the crude drug of following weight portion: Herba Solani Lyrati 20-30 part, Cordyceps 5-15 part, Rhizoma Paridis 10-15 part, Rhizoma Dioscoreae Bulbiferae 10-15 part, Radix Astragali 30-50 part, Semen Momordicae 2-3 part, Scorpio 1-5 part, Pollen Typhae 12-18 part, Holotrichia diomphalia Bates 5-10 part, Radix Panacis Quinquefolii 20-50 part, Carapax Trionycis 20-50 part, Spica Prunellae 20-50 part, Pseudobulbus Cremastrae Seu Pleiones 10-15 part, Bulbus Fritillariae Uninbracteatae 15-20 part, Radix Notoginseng 10-20 part, Eupolyphaga Seu Steleophaga 6-15 part, Scolopendra 20-30 part, Sargassum 30-50 part and Radix Sophorae Tonkinensis 10-15 part.
Preferably, described compositions comprises the crude drug of following weight portion: Herba Solani Lyrati 25 parts, Cordyceps 6 parts, Rhizoma Paridis 12 parts, Rhizoma Dioscoreae Bulbiferae 13 parts, the Radix Astragali 40 parts, Semen Momordicae 2.5 parts, Scorpio 2 parts, Pollen Typhae 15 parts, Holotrichia diomphalia Bates 8 parts, Radix Panacis Quinquefolii 30 parts, Carapax Trionycis 30 parts, Spica Prunellae 30 parts, Pseudobulbus Cremastrae Seu Pleiones 12 parts, Bulbus Fritillariae Uninbracteatae 18 parts, Radix Notoginseng 15 parts, Eupolyphaga Seu Steleophaga 10 parts, Scolopendra 25 parts, Sargassum 40 parts and Radix Sophorae Tonkinensis 12 parts.
More preferably, described compositions also comprises the crude drug of following weight portion: Radix Helicteris Isorae 10 parts, Pericarpium Citri Reticulatae 15 parts, Radix Ilicis Pernyi 20 parts, Radix Angelicae Sinensis 15 parts, Herba Blumeae Lacerae 12 parts, 20 parts, Flos Mume, Herba Limonii Gmelinii 20 parts, 15 parts, Radix Rubiae, Caulis Seu Folium Callicarpae Kwangtungensis 15 parts, Radix Bupleuri 10 parts, Herba Hedyotidis Chrysotrichae 20 parts, Caulis Bambusae In Taenia 10 parts and 12 parts, Radix Glycyrrhizae.
Most preferably, described Chinese medicine is tablet, dispersible tablet, rapidly dissolving tablet, powder, granule or decoction.
In the present compositions, Herba Hedyotidis Chrysotrichae, Radix Helicteris Isorae and Radix Ilicis Pernyi are monarch drug; Herba Solani Lyrati, Cordyceps, Rhizoma Paridis, Rhizoma Dioscoreae Bulbiferae, the Radix Astragali, Pericarpium Citri Reticulatae, Radix Angelicae Sinensis, Herba Blumeae Lacerae are ministerial drug; Semen Momordicae, Scorpio, Pollen Typhae, Holotrichia diomphalia Bates, Radix Panacis Quinquefolii, Carapax Trionycis, Spica Prunellae, Pseudobulbus Cremastrae Seu Pleiones, Bulbus Fritillariae Uninbracteatae, Radix Notoginseng, Eupolyphaga Seu Steleophaga, Scolopendra, Sargassum, Radix Sophorae Tonkinensis, Flos Mume, Herba Limonii Gmelinii, Radix Rubiae, Caulis Seu Folium Callicarpae Kwangtungensis, Radix Bupleuri, Caulis Bambusae In Taenia are adjuvant drug; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, for making medicine, various composition synergism, thus play optimum efficiency.
Use natural drug, blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain in the Chinese medicine composition for the treatment of tumor of the present invention, there is the effects such as circulation of qi promoting removing blood stasis, removing food stagnancy pain relieving, purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, there is instant effect, good effect, the advantage that has no side effect.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The preparation of embodiment decoction of the present invention
Take Herba Solani Lyrati 25 grams, Cordyceps 6 grams, Rhizoma Paridis 12 grams, Rhizoma Dioscoreae Bulbiferae 13 grams, the Radix Astragali 40 grams, Semen Momordicae 2.5 grams, Scorpio 2 grams, Pollen Typhae 15 grams, Holotrichia diomphalia Bates 8 grams, Radix Panacis Quinquefolii 30 grams, Carapax Trionycis 30 grams, Spica Prunellae 30 grams, Pseudobulbus Cremastrae Seu Pleiones 12 grams, Bulbus Fritillariae Uninbracteatae 18 grams, Radix Notoginseng 15 grams, Eupolyphaga Seu Steleophaga 10 grams, Scolopendra 25 grams, Sargassum 40 grams, Radix Sophorae Tonkinensis 12 grams, Radix Helicteris Isorae 10 grams, Pericarpium Citri Reticulatae 15 grams, Radix Ilicis Pernyi 20 grams, Radix Angelicae Sinensis 15 grams, Herba Blumeae Lacerae 12 grams, 20 grams, Flos Mume, Herba Limonii Gmelinii 20 grams, 15 grams, Radix Rubiae, Caulis Seu Folium Callicarpae Kwangtungensis 15 grams, Radix Bupleuri 10 grams, Herba Hedyotidis Chrysotrichae 20 grams, Caulis Bambusae In Taenia 10 grams and 12 grams, Radix Glycyrrhizae, add 8000 ml waters, heat 3 hours at 40 DEG C, filter, obtain filtering residue and filtrate 1, 4000 ml waters are added in filtering residue, heat 1 hour at 40 DEG C, filter, obtain filtrate 2, merging filtrate 1 and 2, be cooled to room temperature, obtain decoction of the present invention.
Toxicity test
Acute toxicity test: application NIH mice 60, SPF level, male and female half and half, body weight 17 ~ 24g, carries out acute toxicity test.Mice is divided into two groups at random, often organizes 30, i.e. matched group and administration group, fasting 12 hours before experiment; The decoction prepared in adjustment embodiment, concentration is made to be 5.26g crude drug/ml, gavage, gavage volume is 5ml/kg (namely unit dosage form is 26.3g crude drug/kg), matched group gives normal saline, administration in a day 2 times, delivery time 6 hours, Continuous Observation 14 days after administration, and record toxic reaction and the death toll of mice.Experimental result shows: compare with matched group, and after administration, mice has no notable difference, and experiment Continuous Observation 14 days, mouse systemic situation, diet, drinking-water, body weight increase all normal.Select to put to death administration group mice, test under microscope: the important organs such as the heart, liver, lung, gastric and thymus, no abnormality seen changes.Mouse oral gavage decoction LD of the present invention
50>26.3g crude drug/kg, every day, maximum dosage-feeding was 52.6g crude drug/kg/ day.Clinical drug dosage of the present invention be 5.64g crude drug/day/people, adult body weight in 60kg, average dosage is 0.094g crude drug/kg/ day.By weighing machine: the dosis tolerata of mice (average weight is in 21g) oral administration gavage Chinese medicine of the present invention is 559 times of quantity.Therefore the pharmaceutical composition acute toxicity that takes orally of the present invention is low, clinical drug safety.
Long term toxicity test: application SD rat, body weight 200g ± 10g, male and female half and half.The decoction prepared in embodiment is used to test.Prepare high, medium and low three dosage groups, be respectively 300,150,75 times of clinical application amount, mix with the normal saline 1:1 containing 2 % by weight Radix Acaciae senegalis.Adopt gastric infusion mode, continuous use 16 weeks (1.0ml/100g body weight, every day 2 times) and drug withdrawal after 4 weeks, result shows: the index such as hair, behavior, defecation, body weight, organ weights, hemogram, hepatic and renal function, blood glucose, blood fat of medicine of the present invention to rat all has no significant effect, internal organs naked eyes do not find that difference change and histological indications show, medication 16 weeks and drug withdrawal are after 4 weeks, and each internal organs of rat are all without obviously changing.Illustrate that the pharmaceutical composition that the present invention is taken orally is little to toxicity after rat long-term prescription, also there is no difference reaction after drug withdrawal, application safety.
Experimental example
Diagnostic criteria
The hysteromyoma diagnostic criteria of formulating with reference to " new Chinese medicine guideline of clinical investigations " (Ministry of Health of the People's Republic of China. new Chinese medicine guideline of clinical investigations [S]. the 1st volume of .1993:272-273) specific as follows: be divided into intramural myoma, Subserous myoma and fleshy polyp.According to gynecologic inspection and ultrasound diagnosis to make a definite diagnosis.Choose and meet diagnosing tumor standard patient 50 example, 45 years old mean age, average course of disease 2.5 years (the shortest 2 months, the longest 5 years); Intramural myoma 15 example, Subserous myoma 20 example and fleshy polyp 15 example is confirmed, all with menorrhagia or menostaxis through B ultrasonic.Before treatment, muscular tumor diameter is in patient 18 example of below 3.0cm, and muscular tumor diameter is in patient 32 example of more than 3.0cm.
Use decoction obtained in embodiment to treat, wherein one day 2 times, clinical drug dosage be 5.64g crude drug/day/people, treat 3 months is a course for the treatment of, treats 2 courses for the treatment of continuously.
Criterion of therapeutical effect
Recovery from illness: muscular tumor disappears, the eumenorrhea.Effective: muscular tumor reduces 0.5cm
3above, the eumenorrhea; Or muscular tumor disappears, menstrual symptom is without change.Effective: clinical symptom relief or disappearance, muscular tumor reduces, and menstruation is without improvement; Or muscular tumor is unchanged, the eumenorrhea.Invalid: muscular tumor is unchanged or increase, and menstruation is without change.
Result
Through treatment, 18 examples of fully recovering in 50 routine patients, effective 12 examples, effective 15 examples, invalid 5 examples, total effective rate is 90%.
Claims (8)
1. treat the Chinese medicine composition of tumor for one kind, it is characterized in that, it comprises the crude drug of following weight portion: Herba Solani Lyrati 20-30 part, Cordyceps 5-15 part, Rhizoma Paridis 10-15 part, Rhizoma Dioscoreae Bulbiferae 10-15 part, Radix Astragali 30-50 part, Semen Momordicae 2-3 part, Scorpio 1-5 part, Pollen Typhae 12-18 part, Holotrichia diomphalia Bates 5-10 part, Radix Panacis Quinquefolii 20-50 part, Carapax Trionycis 20-50 part, Spica Prunellae 20-50 part, Pseudobulbus Cremastrae Seu Pleiones 10-15 part, Bulbus Fritillariae Uninbracteatae 15-20 part, Radix Notoginseng 10-20 part, Eupolyphaga Seu Steleophaga 6-15 part, Scolopendra 20-30 part, Sargassum 30-50 part and Radix Sophorae Tonkinensis 10-15 part.
2. the Chinese medicine composition for the treatment of tumor according to claim 1, it is characterized in that, it comprises the crude drug of following weight portion: Herba Solani Lyrati 25 parts, Cordyceps 6 parts, Rhizoma Paridis 12 parts, Rhizoma Dioscoreae Bulbiferae 13 parts, the Radix Astragali 40 parts, Semen Momordicae 2.5 parts, Scorpio 2 parts, Pollen Typhae 15 parts, Holotrichia diomphalia Bates 8 parts, Radix Panacis Quinquefolii 30 parts, Carapax Trionycis 30 parts, Spica Prunellae 30 parts, Pseudobulbus Cremastrae Seu Pleiones 12 parts, Bulbus Fritillariae Uninbracteatae 18 parts, Radix Notoginseng 15 parts, Eupolyphaga Seu Steleophaga 10 parts, Scolopendra 25 parts, Sargassum 40 parts and Radix Sophorae Tonkinensis 12 parts.
3. the Chinese medicine composition for the treatment of tumor according to claim 2, it is characterized in that, it also comprises the crude drug of following weight portion: Radix Helicteris Isorae 10 parts, Pericarpium Citri Reticulatae 15 parts, Radix Ilicis Pernyi 20 parts, Radix Angelicae Sinensis 15 parts, Herba Blumeae Lacerae 12 parts, 20 parts, Flos Mume, Herba Limonii Gmelinii 20 parts, 15 parts, Radix Rubiae, Caulis Seu Folium Callicarpae Kwangtungensis 15 parts, Radix Bupleuri 10 parts, Herba Hedyotidis Chrysotrichae 20 parts, Caulis Bambusae In Taenia 10 parts and 12 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition for the treatment of tumor according to claim 3, is characterized in that, described Chinese medicine composition is tablet, dispersible tablet, rapidly dissolving tablet, powder, granule or decoction.
5. the purposes of compositions in the Chinese medicine of preparation treatment tumor, it is characterized in that, described compositions comprises the crude drug of following weight portion: Herba Solani Lyrati 20-30 part, Cordyceps 5-15 part, Rhizoma Paridis 10-15 part, Rhizoma Dioscoreae Bulbiferae 10-15 part, Radix Astragali 30-50 part, Semen Momordicae 2-3 part, Scorpio 1-5 part, Pollen Typhae 12-18 part, Holotrichia diomphalia Bates 5-10 part, Radix Panacis Quinquefolii 20-50 part, Carapax Trionycis 20-50 part, Spica Prunellae 20-50 part, Pseudobulbus Cremastrae Seu Pleiones 10-15 part, Bulbus Fritillariae Uninbracteatae 15-20 part, Radix Notoginseng 10-20 part, Eupolyphaga Seu Steleophaga 6-15 part, Scolopendra 20-30 part, Sargassum 30-50 part and Radix Sophorae Tonkinensis 10-15 part.
6. purposes according to claim 5, it is characterized in that, described compositions comprises the crude drug of following weight portion: Herba Solani Lyrati 25 parts, Cordyceps 6 parts, Rhizoma Paridis 12 parts, Rhizoma Dioscoreae Bulbiferae 13 parts, the Radix Astragali 40 parts, Semen Momordicae 2.5 parts, Scorpio 2 parts, Pollen Typhae 15 parts, Holotrichia diomphalia Bates 8 parts, Radix Panacis Quinquefolii 30 parts, Carapax Trionycis 30 parts, Spica Prunellae 30 parts, Pseudobulbus Cremastrae Seu Pleiones 12 parts, Bulbus Fritillariae Uninbracteatae 18 parts, Radix Notoginseng 15 parts, Eupolyphaga Seu Steleophaga 10 parts, Scolopendra 25 parts, Sargassum 40 parts and Radix Sophorae Tonkinensis 12 parts.
7. purposes according to claim 6, it is characterized in that, described compositions also comprises the crude drug of following weight portion: Radix Helicteris Isorae 10 parts, Pericarpium Citri Reticulatae 15 parts, Radix Ilicis Pernyi 20 parts, Radix Angelicae Sinensis 15 parts, Herba Blumeae Lacerae 12 parts, 20 parts, Flos Mume, Herba Limonii Gmelinii 20 parts, 15 parts, Radix Rubiae, Caulis Seu Folium Callicarpae Kwangtungensis 15 parts, Radix Bupleuri 10 parts, Herba Hedyotidis Chrysotrichae 20 parts, Caulis Bambusae In Taenia 10 parts and 12 parts, Radix Glycyrrhizae.
8. purposes according to claim 7, is characterized in that, described Chinese medicine is tablet, dispersible tablet, rapidly dissolving tablet, powder, granule or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510010589.8A CN104491459A (en) | 2015-01-09 | 2015-01-09 | Traditional Chinese medicine composition for treating tumors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510010589.8A CN104491459A (en) | 2015-01-09 | 2015-01-09 | Traditional Chinese medicine composition for treating tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104491459A true CN104491459A (en) | 2015-04-08 |
Family
ID=52932973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510010589.8A Pending CN104491459A (en) | 2015-01-09 | 2015-01-09 | Traditional Chinese medicine composition for treating tumors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104491459A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168259A (en) * | 2015-10-16 | 2015-12-23 | 四川和济健康管理有限公司 | Formulated traditional Chinese medicine composition for preventing and/or treating tumors, traditional Chinese medicine preparation and application |
| CN108686100A (en) * | 2018-04-13 | 2018-10-23 | 涂冲林 | A kind of Chinese medicine composition for treating neoplastic disease |
| CN110801491A (en) * | 2018-07-18 | 2020-02-18 | 陈德彬 | A Chinese medicinal composition for treating tumor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872324A (en) * | 2006-04-05 | 2006-12-06 | 张忠 | Medication for treating hysteromyoma |
| KR20110058041A (en) * | 2009-11-25 | 2011-06-01 | 주식회사한국신약 | Health functional foods compositions for the prevention and amelioration of cancer containing the mixed extract of phellinus linteus mycelium and cultured panax ginseng cameyer as an active ingredient |
| CN102885925A (en) * | 2011-07-22 | 2013-01-23 | 刘金生 | Chinese medicinal preparation for treating deficiency of qi and blood, qi stagnation and blood stasis |
-
2015
- 2015-01-09 CN CN201510010589.8A patent/CN104491459A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872324A (en) * | 2006-04-05 | 2006-12-06 | 张忠 | Medication for treating hysteromyoma |
| KR20110058041A (en) * | 2009-11-25 | 2011-06-01 | 주식회사한국신약 | Health functional foods compositions for the prevention and amelioration of cancer containing the mixed extract of phellinus linteus mycelium and cultured panax ginseng cameyer as an active ingredient |
| CN102885925A (en) * | 2011-07-22 | 2013-01-23 | 刘金生 | Chinese medicinal preparation for treating deficiency of qi and blood, qi stagnation and blood stasis |
Non-Patent Citations (4)
| Title |
|---|
| 冯怀英等: "《桐山济寿稿》", 31 May 2012 * |
| 张民庆等: "《抗肿瘤中药的临床应用》", 30 September 1998 * |
| 成都中医学院: "《中药学》", 31 December 1978 * |
| 陈国新等: "《陈恩中医世家经验辑要》", 30 September 2004 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168259A (en) * | 2015-10-16 | 2015-12-23 | 四川和济健康管理有限公司 | Formulated traditional Chinese medicine composition for preventing and/or treating tumors, traditional Chinese medicine preparation and application |
| CN108686100A (en) * | 2018-04-13 | 2018-10-23 | 涂冲林 | A kind of Chinese medicine composition for treating neoplastic disease |
| CN110801491A (en) * | 2018-07-18 | 2020-02-18 | 陈德彬 | A Chinese medicinal composition for treating tumor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103301400A (en) | Traditional Chinese medicinal composition for treating chronic atrophic gastritis and preparation method of traditional Chinese medicinal composition | |
| CN102961508A (en) | Traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN101007157A (en) | Traditional Chinese medicine compound preparation for treating chronic cholecystitis | |
| CN107468768B (en) | Qiang medicine composition and application thereof | |
| CN105311492A (en) | Medicine for treating coronary atherosclerotic heart disease | |
| CN104547902A (en) | Application of traditional Chinese preparation in preparation of drugs used for treating chronic enteritis and appendicitis | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN104606554A (en) | Agentia for treating blood-stasis type non-stop lochia after delivery | |
| CN104622995A (en) | Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition | |
| CN104587389A (en) | Traditional Chinese medicine composition for treating neck shoulder pain and lumbocrural pain | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN103948899A (en) | Traditional Tibetan medicine for treating atrophic gastritis | |
| CN115089674B (en) | Traditional Chinese medicine composition for preventing and treating gout by melting urate calculi, and preparation method and application thereof | |
| CN115040576B (en) | Pharmaceutical composition for treating acute pancreatitis | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
| CN100333777C (en) | Medicine for improving enterogastric function after radiation chemiotherapy | |
| CN105853940A (en) | Traditional Chinese medicine for treating bile disease | |
| CN105434808A (en) | Traditional Chinese medicine composition for treating hemorrhoids and preparation method thereof | |
| CN104474513A (en) | Medicine for treating endometriosis | |
| CN104398827A (en) | Medicament for treating bronchial asthma | |
| CN110801491A (en) | A Chinese medicinal composition for treating tumor | |
| CN103768536B (en) | A kind of Chinese medicine for the treatment of dysmenorrhea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150408 |
|
| RJ01 | Rejection of invention patent application after publication |